Entera Bio

Entera Bio ROCE

The Return on Capital Employed (ROCE) of Entera Bio (ENTX) as of Oct 8, 2026 is -88.00 %. In the previous year, Return on Capital Employed (ROCE) was -118.63 % — a change of -25.82% (higher).

ROCE

-88.00 %

YoY

-25.82%

Last updated:

In 2025, Entera Bio's return on capital employed (ROCE) was -88.00 %, a -25.82% increase from the -118.63 % ROCE in the previous year.

The Entera Bio ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-107.36 USD
Jan 1, 2019
-96.10 USD
Jan 1, 2020
-148.24 USD
Jan 1, 2021
-54.14 USD
Jan 1, 2022
-110.75 USD
Jan 1, 2023
-86.08 USD
Jan 1, 2024
-118.63 USD
Jan 1, 2025
-88.00 USD
The Entera Bio ROCE history
YEARROCEYoY
-88.00 %-25.82%
-118.63 %+37.81%
-86.08 %-22.27%
-110.75 %+104.55%
-54.14 %-63.48%
-148.24 %+54.26%
-96.10 %-10.49%
-107.36 %+198.71%
-35.94 %-269.08%
21.26 %+47.55%
14.41 %—
Access this data via the Eulerpool API

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Entera Bio's Return on Capital Employed (ROCE)

Entera Bio's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Entera Bio's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Entera Bio's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Entera Bio’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Entera Bio stock

Return on Capital Employed (ROCE) of Entera Bio is -88.00 % in 2025.

Return on Capital Employed (ROCE) of Entera Bio changed from -118.63 % to -88.00 %, representing a -25.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Entera Bio since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Entera Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

Profitability — Entera Bio

All Key Metrics — Entera Bio